Humira (adalimumab) NDC 83457-243

NDC codes

FDA NDC Directory

Product NDC (as listed)83457-243Labeler and product segments. Claims need a package NDC.

Product NDC at billing width83457-0243Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
83457-243-02	83457024302	2 KIT in 1 CARTON (83457-243-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY (83457-242-01) / .4 mL in 1 SYRINGE * 1 mL in 1 PACKET (83457-927-01)Marketed from Feb 14, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Humira
Generic name (nonproprietary): adalimumab
Dosage form: Kit
Labeler: Cordavis Limited
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125057
Marketing start: Feb 14, 2024
Listing expires: Dec 31, 2027
Identifiers: Product ID 83457-243_5fe81b1a-cc31-444e-a0f1-1ea4f7334b89SPL ID 5fe81b1a-cc31-444e-a0f1-1ea4f7334b89SPL set ID 4977567e-3525-44ac-9ff5-f1e74b053950RxCUI 797544, 1726844, 1726846, 1872979, 1872980, 1921009, 1921010, 1921016, 1921017, 1921238, 1921240

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N483457024302 followed by a unit qualifier and the quantity

Package 83457-0243-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 23, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 125057

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 125057
Product	Strength	Form · route	Labeler	Product NDC
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-0817
Humiraadalimumab	—	Kit	A-S Medication Solutions	50090-4487
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-0243
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-2540
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-0554
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-0616
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-3799
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-0124
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-4339
Humiraadalimumab	—	Kit	AbbVie Inc.	0074-1539
Humiraadalimumab	—	Kit	Cordavis Limited	83457-124
Humiraadalimumab	—	Kit	Cordavis Limited	83457-616
Humiraadalimumab	—	Kit	Cordavis Limited	83457-554
Humiraadalimumab	—	Kit	Cordavis Limited	83457-817